AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-26. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Variation === The lobes of the lung are subject to anatomical variations. A horizontal interlobar fissure was found to be incomplete in 25% of right lungs, or even absent in 11% of all cases. An accessory fissure was also found in 14% and 22% of left and right lungs, respectively. An oblique fissure was found to be incomplete in 21% to 47% of left lungs. In some cases a fissure is absent, or extra, resulting in a right lung with only two lobes, or a left lung with three lobes. A variation in the airway branching structure has been found specifically in the central airway branching. This variation is associated with the development of COPD in adulthood.
=== Other === Chest pain may be accompanied by sweating, nausea or vomiting, and fainting, and these symptoms may also occur without any pain at all. Dizziness or lightheadedness is common and occurs due to reduction in oxygen and blood to the brain. In females, the most common symptoms of myocardial infarction include shortness of breath, weakness, and fatigue. Females are more likely to have unusual or unexplained tiredness and nausea or vomiting as symptoms. Females having heart attacks are more likely to have palpitations, back pain, labored breath, vomiting, and left arm pain than males, although the studies showing these differences had high variability. Females are less likely to report chest pain during a heart attack and more likely to report nausea, jaw pain, neck pain, cough, and fatigue, although these findings are inconsistent across studies. Females with heart attacks also had more indigestion, dizziness, loss of appetite, and loss of consciousness. Shortness of breath is a common, and sometimes the only symptom, occurring when damage to the heart limits the output of the left ventricle, with breathlessness arising either from low oxygen in the blood or pulmonary edema. Other less common symptoms include weakness, light-headedness, palpitations, and abnormalities in heart rate or blood pressure. These symptoms are likely induced by a massive surge of catecholamines from the sympathetic nervous system, which occurs in response to pain and, where present, low blood pressure.
=== Malta === The Parliament of Malta consists of the president of Malta and the House of Representatives of 69 members (article 51 of the Constitution), referred to as "members of Parliament" (article 52(1) of the Constitution). When appointed from outside the House, the speaker is also considered a member of the Parliament. The Constitution lists the qualifications and disqualifications from serving as a member of Parliament. Privileges of members of Parliament and their Code of Ethics are laid out in the House of Representatives (Privileges and Powers) Ordinance.
==== New driver's license system ==== The National Traffic Council (Contran) approved a resolution in December 2025 ending the requirement that all theoretical and practical classes for obtaining a Brazilian driver's license (CNH) in categories A (motorcycles) and B (cars) must be taken exclusively at driving schools (CFC). The government will provide a free digital theoretical course. Practical lessons may be conducted with accredited independent instructors, including using a personal vehicle, or at driving schools. The minimum duration of lessons has been reduced from 25 hours to 2 hours. Biometric registration, theoretical and practical examinations, and medical tests remain mandatory. The reduction in costs is estimated at 70%. The Brazilian Manual of Driving Examinations was updated with unified guidelines for driving tests nationwide, eliminating parallel parking as a mandatory stage and revising the criteria for approval and failure. Each infraction now receives a specific score, and candidates are approved only if they do not exceed a limit of 10 points. The rule of a single infraction leading to immediate failure was eliminated. Beginning in January 2026, automatic and free license renewal was introduced for drivers considered to have a good record—those who have no points on their license in the previous 12 months, no recorded traffic infractions in that period, and who are registered in the National Positive Drivers Registry (RNPC). Drivers over the age of 70 are not eligible for automatic renewal, and drivers over 50 may renew automatically only once.
=== Analgesia and abuse liability === Recent studies indicate that targeting NOP is a promising alternative route to relieving pain without the deleterious side effects of traditional MOP-activating opioid therapies. In primates, specifically activating NOP through systemic or intrathecal administration induces long-lasting, morphine-comparable analgesia without causing itch, respiratory depression, or the reinforcing effects that lead to addiction in an intravenous self-administration paradigm; thus eliminating all of the serious side-effects of current opioid therapies. Several commonly used opioid drugs including etorphine and buprenorphine have been demonstrated to bind to nociceptin receptors, but this binding is relatively insignificant compared to their activity at other opioid receptors in the acute setting (however the non-analgesic NOPr antagonist SB-612,111 was demonstrated to potentiate the therapeutic benefits of morphine). Chronic administration of nociceptin receptor agonists results in an attenuation of the analgesic and anti-allodynic effects of opiates; this mechanism inhibits the action of endogenous opioids as well, resulting in an increase in pain severity, depression, and both physical and psychological opiate dependence following chronic NOPr agonist administration. Administration of the NOPr antagonist SB-612,111 has been shown to inhibit this process. More recently a range of selective ligands for NOP have been developed, which show little or no affinity to other opioid receptors and so allow NOP-mediated responses to be studied in isolation.
Sources: en.wikipedia.org
== Discovery == The protein was first isolated in 1987 by Thomas J. Martin's team at the University of Melbourne. Miao et al. showed that disruption of the PTHrP gene in mice caused a lethal phenotype and distinct bone abnormalities, suggesting that PTHrP has a physiological function.
Commissioned officers, British and Indian, held identical ranks to commissioned officers of the British Army. King's Commissioned Indian Officers (KCIOs), created from the 1920s, held equal powers to British officers. Viceroy's Commissioned Officers were Indians holding officer ranks. They were treated in almost all respects as commissioned officers, but had authority over Indian troops only, and were subordinate to all British King's (and Queen's) Commissioned Officers and KCIOs. They included Subedar Major or Risaldar-Major (Cavalry), equivalents to a British Major; Subedar or Risaldar (Cavalry) equivalents to Captain; and Jemadars equivalent to Lieutenant.
About 75% of human disease-causing genes have a functional equivalent in the fruit fly genome Its care and culture require little equipment, space, and expense even when using large cultures. It can be safely and readily anesthetized (usually with ether, carbon dioxide gas, by cooling, or with products such as FlyNap). Its morphology is easy to identify once anesthetized. It has a short generation time (about 10 days at room temperature), so several generations can be studied within a few weeks. It has a high fecundity (females lay up to 100 eggs per day, and perhaps 2,000 in a lifetime). Males and females are readily distinguished, and virgin females can be easily identified by their light-colored, translucent abdomen, facilitating genetic crossing. The mature larva has giant chromosomes in the salivary glands called polytene chromosomes, "puffs", which indicate regions of transcription, hence gene activity. The under-replication of rDNA occurs resulting in only 20% of DNA compared to the brain. Compare to the 47%, less rDNA in Sarcophaga barbata ovaries. It has only four pairs of chromosomes—three autosomes, and one pair of sex chromosomes. Males do not show meiotic recombination, facilitating genetic studies. Recessive lethal "balancer chromosomes" carrying visible genetic markers can be used to keep stocks of lethal alleles in a heterozygous state without recombination due to multiple inversions in the balancer. The development of this organism—from fertilized egg to mature adult—is well understood. Genetic transformation techniques have been available since 1987.
From then on, through to 2016 there was a period of extended stability for the markets, until in April when the large Nucleus marketplace collapsed for unknown reasons, taking escrowed coins with it. On April 28, investigations into the Italian Darknet Community (IDC) forum-based marketplace led to a number of key arrests. In May 2017, the Bloomsfield Market closed after investigations in Slovakia inadvertently led to the arrests of its operators. Later that month, the long-lived Outlaw market closed down citing a major bitcoin cryptocurrency wallet theft; however, speculation remained that it was an exit scam. In July 2017, the markets experienced their largest disruptions since Operation Onymous, when Operation Bayonet culminated in coordinated multinational seizures of both the Hansa and leading AlphaBay markets, sparking worldwide law enforcement investigations. The seizures brought in lots of traffic to other markets making TradeRoute and Dream Market the most popular markets at the time. In October 2017, TradeRoute exit-scammed shortly after being hacked and extorted. In June 2018, the digital security organization Digital Shadows reported that, due to the climate of fear and mistrust after the closure of AlphaBay and Hansa, darknet market activity was switching away from centralized marketplace websites and towards alternatives such as direct chat on Telegram, or decentralized marketplaces like OpenBazaar.
=== High Voltage Power Corporation === In July 1968, High Voltage Engineering Corporation and Reynolds Metals Company announced they would form a joint venture partnership to develop, produce, and sell gas-insulated systems for transmission of electric power. The venture, High Voltage Power Corporation, aimed to commercialize technology for underground electric power transmission. HVEC president Denis Robinson noted increasing need by bury transmission lines underground for technological, economic, and aesthetic reasons, and emphasizing that compressed gas offered unique advantages for transmitting large amounts of power at high voltages with increased reliability at lower cost. Each company held a 50% interest in the venture, with Reynolds providing funds and technical research while HVEC contributed its patents, licenses, and know-how. The development work was carried out at HVEC's Burlington factory. The subsidiary's products included insulating-core reactors for nuclear power plants and gas-insulated transmission systems for electrical utilities, based on Van de Graaff's insulating-core transformer invention. However, by 1974, High Voltage Power Corp. losses were consuming 60-75% of HVEC's cash flow despite generating only $1.5-2 million in annual sales, leading HVEC to divest from the subsidiary.
Sources: en.wikipedia.org
=== Early life === McKinty was born in Belfast, Northern Ireland in 1968. The fourth of five children, he grew up in the Victoria area of Carrickfergus, County Antrim. His father was a welder and boilermaker at the Harland and Wolff shipyard before becoming a merchant seaman. He grew up reading science fiction and crime novels by the likes of Ursula Le Guin, J G Ballard and Jim Thompson. He studied law at the University of Warwick and politics and philosophy at the University of Oxford. After graduating from Oxford in 1993, McKinty moved to New York and found work in a number of occupations: security guard, barman, bookstore clerk, rugby coach, door to door salesman and librarian for the Columbia University Library. In 1999, while his wife studied for a Fulbright in Israel, McKinty played loose head prop forward for the Jerusalem Lions Rugby Club. In 2000, he relocated to Denver, Colorado, to become a high school English teacher.
One night, she ends up at a bar where her father works. After getting into an altercation with a man at the bar, she vents her frustrations at her father (who prevents her from driving home), claiming she is like him; however, she stays the night at her father's place and reconnects with him; he says she's not like him but is like her mother. Ryan later gets hurt and is discharged, and Amber goes to visit him in the hospital, but Ryan's mother shows up and insists he return to Wyoming. Later, Amber finds out she is pregnant with Ryan's child. However, she exhibits a strong want to raise the child on her own without his help (especially after talking with Drew, who drove her to Wyoming so she could give the news to Ryan and refused to leave her there). In the penultimate episode of the series, Amber gives birth to a son, whom she names Ezekiel (Zeek) after her grandfather. Because she is struggling in her small apartment, Zeek and Camille invite Amber and her baby to move in with them, to which she happily agrees. After an undisclosed amount of time, Amber is now married to a man with whom she has a young daughter, while Ryan remains a part of his son's life.
Life Length is a biotechnology company. Founded in 2010 by Stephen J. Matlin and Dr. María Blasco Marhuenda, the company provides telomere diagnostics as well as telomerase measurement. Life Length is Spain's only federally-accredited laboratory under CLIA. It has three main facilities, with offices in Madrid and laboratories located in Tres Cantos.
== L == Larock indole synthesis Lawesson's reagent Lebedev process Lehmstedt–Tanasescu reaction Leimgruber–Batcho indole synthesis Letts nitrile synthesis Leuckart reaction Leuckart thiophenol reaction Leuckart–Wallach reaction Leuckart amide synthesis Levinstein process Ley–Griffith oxidation, Ley oxidation Lieben iodoform reaction, Haloform reaction Liebeskind–Srogl coupling Liebig melamine synthesis Lindlar catalyst Lobry de Bruyn–Van Ekenstein transformation Lombardo methylenation Lossen rearrangement Lucas' reagent Luche reduction
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.